GEO DataSets

(Submitter supplied) Candida auris, a multidrug-resistant human fungal pathogen, was first identified in 2009 in Japan. Since then, systemic C. auris infections have now been reported in more than 50 countries, with mortality rates of 30-60%. A major contributing factor to its high inter- and intrahospital clonal transmission is that C. auris, unlike most Candida species, displays unique skin tropism and can stay on human skin for a prolonged period. more...

Organism:

Candidozyma auris

Type:

Expression profiling by high throughput sequencing

Platform:

GPL29671

6 Samples

Download data: TXT

(Submitter supplied) The emergence of Candida auris poses a significant health challenge that has led to a new era of multidrug-resistant fungal infections. Invasive infections caused by C. auris are usually associated with remarkable morbidity and mortality. For many years, amphotericin B (AmB) remained the most efficient and the last line of treatment against most hard-to-treat fungal infections. However, strains of C. more...

Organism:

Candidozyma auris

Type:

Expression profiling by high throughput sequencing

Platform:

GPL28368

3 Samples

Download data: XLSX

(Submitter supplied) Invasive fungal infections are important healthcare associated disease worldwide especially in intensive care units More recently, Candida auris a multidrug and potentially pan-resistant species has globally emerged as a new nosocomial pathogen, which has been already reported from at least 50 countries on six continents. Clinical studies showed that previously well-defined phylogenetic C. auris clades display significant differences regarding their pathogenicity, virulence, metabolism and susceptibility profile to traditional antifungal therapies. more...

Organism:

Candidozyma auris

Type:

Expression profiling by high throughput sequencing

Platform:

GPL24811

8 Samples

Download data: XLSX

(Submitter supplied) Comparative transcriptomic profiling of Candida auris derivative clones collected from 5FC-containing medium in comparison to the Wild-Type Strain

Organism:

Candidozyma auris

Type:

Expression profiling by high throughput sequencing

Platform:

GPL28368

15 Samples

Download data: TXT

(Submitter supplied) Candida auris occupies similar niches in various infections as Pseudomonas aeruginosa; however, the details of their interspecies communication remain largely unknown. To gain deeper insights into this bacterial–fungal relationship, phenotypic and transcriptomic analyses were conducted in the presence of the primary P. aeruginosa quorum-sensing molecule, 3-oxo-C12-homoserine lactone (HSL), against C. more...

Organism:

Candidozyma auris; Candida albicans

Type:

Expression profiling by high throughput sequencing

Platforms:

GPL22403 GPL24811

24 Samples

Download data: XLSX

(Submitter supplied) The pathogenic yeast Candida auris represents a global threat of the utmost clinical relevance. This emerging fungal species is remarkable in its resistance to commonly used antifungal and its persistence in the nosocomial settings. The innate immune system is one the first lines of defense preventing the dissemination of pathogens in the host. C. auris is susceptible to circulating phagocytes, namely neutrophils. more...

Organism:

Candidozyma auris

Type:

Expression profiling by high throughput sequencing

Platform:

GPL28368

6 Samples

Download data: SF

(Submitter supplied) Candida auris has emerged as a significant healthcare-associated pathogen, posing a serious challenge due to its multidrug-resistant nature. Given the pre-existing constraints in the discovery and provision of new antifungals, there is thus an urgent imperative to design effective strategies to tackle this pressing global concern. Here, we screened a chemical library and identified phenyl-carbohydrazide derivatives with potent activity against both C. more...

Organism:

Candida albicans SC5314; Candidozyma auris

Type:

Expression profiling by high throughput sequencing; Other

Platforms:

GPL33190 GPL28368 GPL34459

24 Samples

Download data: TXT

(Submitter supplied) Candida auris has emerged as a problematic fungal pathogen associated with high morbidity and mortality. Amphotericin B (AmB) is the most effective antifungal used to treat invasive fungal candidiasis, with resistance rarely observed among clinical isolates. However, C. auris possesses extraordinary resistant profiles against all available antifungal drugs, including AmB. In our pursuit of potential solutions, we conducted a screening of a panel of 727 FDA-approved drugs and identified the proton pump inhibitor lansoprazole (LNP) as a potent enhancer of AmB’s activity against C. more...

Organism:

Candidozyma auris

Type:

Expression profiling by high throughput sequencing

Platform:

GPL28368

12 Samples

Download data: XLSX

(Submitter supplied) This study aimed to characterise the transcriptional response of two strains of Candida auris (UACa11 and UACa20) during media-induced aggregation due to differences in phenotype. RNA was isolated from each strain under both aggregating and non-aggregating culture conditions.

Organism:

Candidozyma auris

Type:

Expression profiling by high throughput sequencing

Platform:

GPL24811

12 Samples

Download data: TXT

(Submitter supplied) Candida auris is frequently associated with biofilm-related invasive infections. The resistant profile of these biofilms necessitates innovative therapeutic options, where quorum sensing may be a potential target. Farnesol and tyrosol are two fungal quorum-sensing molecules with antifungal effects at supraphysiological concentrations. Here, we performed genome-wide transcript profiling with C. auris biofilms following farnesol or tyrosol exposure using transcriptome sequencing (RNA-Seq). more...

Organism:

Candidozyma auris

Type:

Expression profiling by high throughput sequencing

Platform:

GPL24811

9 Samples

Download data: XLSX

(Submitter supplied) The goal of this RNA-Seq study is to elucidate Rpn4’s function in regulating C. auris fluconazole resistance.

Organism:

Candidozyma auris

Type:

Expression profiling by high throughput sequencing

Platform:

GPL28368

9 Samples

Download data: TXT

(Submitter supplied) Candida auris is an enigmatic fungal pathogen, recently elevated to the Critical Priority group of fungal pathogens by the World Health Organisation. Of key concern is its ability to cause outbreaks within intensive and chronic care units, which is facilitated through biofilm formation. We investigated the susceptibility of phenotypically-diverse C. auris isolates to sodium hypochlorite (NaOCl) disinfection, and the subsequent role of biofilms in surviving disinfection using a dry-surface biofilm (DSB) model and transcriptomic profiling. more...

Organism:

Candidozyma auris

Type:

Expression profiling by high throughput sequencing

Platform:

GPL28368

12 Samples

Download data: TXT

(Submitter supplied) Tyrosol, a secondary metabolite of Candida species, regulates fungal morphogenesis, and its application may represent a novel innovative therapy against emerging multi-resistant fungal superbug such as Candida auris. In the current study, the effects of tyrosol on growth, redox homeostasis, intracellular microelement contents and activities of virulence-related enzymes released by C. auris were examined. more...

Organism:

Candidozyma auris

Type:

Expression profiling by high throughput sequencing

Platform:

GPL24811

6 Samples

Download data: XLSX

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:

Candidozyma auris; Candida albicans

Type:

Expression profiling by high throughput sequencing

Platforms:

GPL28323 GPL28368

30 Samples

Download data

(Submitter supplied) Goal of this study was to investigate the metabolic adaptation of C. auris to different carbon sources (malic acid, α-ketoglutarate, proline) and nitrogen sources (dipeptides). As a control medium with glucose as carbon source and ammonium sulfate as nitrogen source was used. Transcriptional profiles were compared after 4 h incubation at 37°C.

Organism:

Candidozyma auris

Type:

Expression profiling by high throughput sequencing

Platform:

GPL28368

15 Samples

Download data: CSV

(Submitter supplied) Candida auris is an emerging multidrug-resistant human fungal pathogen often refractory to treatment by all classes of antifungal drugs. Amphotericin B (AmB) is a fungicidal drug that, despite its toxic side effects, remains a drug of choice for the treatment of drug-resistant fungal infections, including those caused by C. auris. However, the molecular mechanisms underlying AmB resistance are poorly understood. more...

Organism:

Candidozyma auris

Type:

Expression profiling by high throughput sequencing

Platform:

GPL28368

12 Samples

Download data: TXT, XLSX

(Submitter supplied) PAT-seq approach was utilised to determine the gene expression in the the transcriptome of C. auris treated with the vehicle DMSO or drug pyrvvinium pamoate (PP). Biological triplicates of C. auris cultures grown in RPMI medium with either DMSO or 1uM PP for 30 minutes at 37 Celsius were havested and total RNA was isolated using standard procedures (hot phenol method).

Organism:

Candidozyma auris

Type:

Expression profiling by high throughput sequencing; Other

Platform:

GPL30240

6 Samples

Download data: CSV

(Submitter supplied) Transcriptomic analysis of different Candida auris clinical isolates

Organism:

Candidozyma auris

Type:

Expression profiling by high throughput sequencing

Platform:

GPL28368

15 Samples

Download data: TXT

(Submitter supplied) To mimic the initial phases of systemic Candida infections with dissemination via the bloodstream, we used an ex vivo whole blood infection model. Dual TP of C. auris in blood gave insights into fungal adaptations and survival mechanisms as well as the host response to the infection.

Organism:

Candidozyma auris; Homo sapiens

Type:

Expression profiling by high throughput sequencing

Platform:

GPL30319

18 Samples

Download data: CSV

(Submitter supplied) The antifungal resistance threat posed by Candida auris necessitates bold and innovative therapeutic options. Farnesol, a quorum-sensing molecule with a potential antifungal and/or adjuvant effect; it may be a promising candidate in alternative treatment regimens. To gain further insights into the farnesol-related effect on C. auris, genome-wide gene expression analysis was performed using RNA-Seq. Farnesol exposure resulted in 1,766 differentially expressed genes. Of these, 447 and 304 genes with at least 1.5-fold increase or decrease in expression, respectively, were selected for further investigation. Genes involved in morphogenesis, biofilm events (maturation and dispersion), gluconeogenesis, iron metabolism, and regulation of RNA biosynthesis showed down-regulation, whereas those related to antioxidative defense, transmembrane transport, glyoxylate cycle, fatty acid β-oxidation, and peroxisome processes were up-regulated. In addition, farnesol treatment increased the expression of certain efflux pump genes, including MDR1, CDR1, and CDR2. Growth, measured by change in CFU number, was significantly inhibited within 2 hours of the addition of farnesol (5.8×10^7±1.1×10^7 and 1.1×10^7±0.3×10^7 CFU/ml for untreated control and farnesol-exposed cells, respectively) (p<0.001). In addition, farnesol treatment caused a significant reduction in intracellular iron (152.2±21.1 vs. 116.0±10.0 mg/kg), manganese (67.9±5.1 vs. 18.6±1.8 mg/kg), and zinc (787.8±22.2 vs. 245.8±34.4 mg/kg) (p<0.05–0.001) compared to untreated control cells, whereas the level of cooper was significantly increased (274.6±15.7 vs. 828.8±106.4 mg/kg) (p<0.001). Our data demonstrate that farnesol significantly influences the growth, intracellular metal ion contents, and gene expression related to fatty acid metabolism, which could open new directions in developing alternative therapies against C. auris.

Organism:

Candidozyma auris

Type:

Expression profiling by high throughput sequencing

Platform:

GPL24811

6 Samples

Download data: XLSX